AChE-IN-63 (Compound 5AD) serves as a selective inhibitor of hAChE, exhibiting an IC 50 value of 0.103 μM. Moreover, it inhibits hBChE and hBACE-1 with IC 50 values of 10 μM and 1.342 μM, respectively. AChE-IN-63 is effective in inhibiting Aβ aggregation and preventing the formation and deposition of Aβ1-42. It can effectively penetrate the blood-brain barrier and is orally bioavailable. This compound is primarily utilized in research related to Alzheimer's disease [1].

hAChE:0.103 μM, hBCHE:10 μM

AChE-IN-63 (5-20 μM; 48 h) inhibits the aggregation of Aβ1-42 in a concentration-dependent manner [1].

AChE-IN-63 (口服；100 mg/kg；单剂量) 在瑞士白化小鼠中未表现毒性或异常反应 [1]。在东莨菪碱Y迷宫模型中，AChE-IN-63 (口服；5-20 mg/kg；单剂量) 改善了认知功能障碍小鼠的学习和记忆，显示出显著的抗氧化活性 [1]。动物模型：东莨菪碱Y迷宫模型 [1]。剂量：5; 10; 20 mg/kg。给药：口服；单剂量。结果：显著提高自发交替行为，降低AChE和MDA水平，并增加CAT水平。